Windlas Biotech Limited has uploaded the transcript of its investor and analyst conference call discussing the unaudited standalone financial results for the quarter ended June 30, 2026. The disclosure, filed on August 14, 2026, follows the initial intimation sent to stock exchanges on August 5, 2026, and provides detailed management commentary on Q1FY27 performance.

Financial Highlights

The company delivered its highest-ever quarterly revenue of ₹248 crore, representing an 18% year-on-year growth. This performance extends Windlas Biotech’s record revenue streak to 14 consecutive quarters. Excluding the impact of non-cash ESOP expenses of ₹7.2 crore, EBITDA grew 26% YoY to ₹34 crore. Profit before tax (PBT) and profit after tax (PAT) grew 27% and 37% YoY to ₹30 crore and ₹25 crore, respectively, on an ex-ESOP basis.

Including ESOP expenses, the company reported EBITDA of ₹27 crore, PBT of ₹23 crore, and PAT of ₹18 crore. Earnings per share improved to ₹8.46.

Key Financial Metrics (Q1FY27)

Shareholder Returns & Capital Allocation

In Q1FY27, Windlas Biotech completed a ₹47 crore share buyback in which promoters did not participate. The company also declared a FY26 final dividend of ₹13 crore, amounting to ₹6.30 per equity share. Management emphasized a focus on long-term shareholder value creation through disciplined execution and operational leverage.

Vertical-wise Performance

The Generic Formulations CDMO vertical drove significant growth, delivering 29% YoY revenue expansion to ₹207 crore. This was attributed to customer expansion, deeper engagement, and new product launches. Injectables have begun contributing to overall revenue, though specific figures were not separately disclosed.

The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products. Management noted that while this vertical faces a temporary momentum hit, long-term growth potential remains supported by geographic expansion and portfolio diversification. The Exports vertical recorded 79% YoY growth to ₹11 crore, benefiting from ongoing registration work and new geography additions.

Capacity Expansion & Outlook

Windlas Biotech is on track for the commercialization of Plant 6 in H1FY27, which will strengthen manufacturing capacity. Mechanical completion has been achieved, with validations and customer audits ongoing. Management expects the plant to support a revenue run rate of approximately ₹1,100 crore, with potential for further debottlenecking through efficiency initiatives. Quarterly depreciation from Plant 6 is estimated at around ₹30 million initially.

Industry volume growth stood at 3.4% in Q1FY27. While API prices have shown volatility due to geopolitical factors, management noted that working capital levels remained stable by quarter-end despite temporary increases in inventory and receivable days during the period.

Windlas Biotech reported its Q1 consolidated financial results, showing revenue growth on a year-on-year basis even as profitability metrics reflected margin pressure. The company's top line expanded to 2.5B rupees from 2.1B rupees in the corresponding period last year, while net profit remained flat at 177M rupees compared to 177M rupees year-on-year.

Financial Performance at a Glance

The following table summarises Windlas Biotech's key Q1 financial metrics on a year-on-year basis:

Revenue Growth Accompanied by Margin Compression

Windlas Biotech's Q1 revenue rose to 2.5B rupees from 2.1B rupees in the year-ago period, indicating meaningful top-line growth. Despite this revenue increase, the company's EBITDA margin contracted to 10.75% from 12.60% year-on-year. In absolute terms, EBITDA grew only marginally to 267M rupees from 265M rupees, suggesting that operating costs rose broadly in line with, or faster than, revenue during the quarter.

Net Profit Remains Stable Year-on-Year

Consolidated net profit for Q1 stood at 177M rupees, unchanged from 177M rupees reported in the same quarter of the previous year. The flat net profit, despite higher revenues, is consistent with the observed compression in EBITDA margins during the quarter. The results reflect a period where revenue expansion did not translate into proportional bottom-line improvement for the company.